Breaking News Instant updates and real-time market news.

AAAP

Advanced Accelerator

$59.76

1.46 (2.50%)

, NVS

Novartis

$84.57

-0.67 (-0.79%)

08:30
09/28/17
09/28
08:30
09/28/17
08:30

Novartis considering deal to buy Advanced Accelerator, Bloomberg says

Novartis (NVS) has approached Advanced Accelerator Applications (AAAP) about a deal and held talks about a potential acquisition of the radiopharmaceutical company, according to Bloomberg, citing people familiar with the matter. Reference Link

AAAP

Advanced Accelerator

$59.76

1.46 (2.50%)

NVS

Novartis

$84.57

-0.67 (-0.79%)

  • 08

    Nov

  • 26

    Jan

  • 17

    May

AAAP Advanced Accelerator
$59.76

1.46 (2.50%)

06/15/17
JPMS
06/15/17
INITIATION
Target $50
JPMS
Overweight
Advanced Accelerator initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Advanced Accelerator Applications with an Overweight rating and $50 price target. The analyst sees "compelling efficacy" for the company's key product Lutathera in somatostatin receptor positive midgut neuroendocrine tumors. She sees a $600M peak sales opportunity for the drug.
07/27/17
JMPS
07/27/17
UPGRADE
JMPS
Outperform
Advanced Accelerator upgraded to Outperform at JMP Securities
07/27/17
JMPS
07/27/17
UPGRADE
Target $69
JMPS
Outperform
Follow-up: Advanced Accelerator upgraded to Outperform at JMP Securities
As previously reported, JMP Securities upgraded Advanced Accelerator to Outperform from Market Perform with a $69 price target citing the positive CHMP opinion for the marketing authorization of Lutathera for gastroenteropancreatic neuroendocrine tumors.
07/28/17
ADAM
07/28/17
NO CHANGE
Target $60
ADAM
Buy
Advanced Accelerator price target raised to $60 from $47 at Canaccord
Canaccord analyst John Newman raised his price target on Advanced Accelerator to $60 from $47 to reflect a higher pricing estimate for Lutathera and higher confidence in U.S. approval. Newman reiterated his Buy rating on Advanced Accelerator shares.
NVS Novartis
$84.57

-0.67 (-0.79%)

07/26/17
07/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Underperform at Jefferies with analyst Andy Barish saying the current valuation and consensus estimates "now reflect the reality" of Chipotle's path to recovery. 2. Biogen (BIIB) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying the company's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality. 3. DSW (DSW) upgraded to Outperform from Neutral at Wedbush with the firm saying it is more confident that second quarter results will beat expectations and that the company will reiterate its full-year guidance after conducting checks and speaking with the company. 4. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing a strong fiscal 2019 outlook. 5. Novartis (NVS) upgraded to Overweight from Underweight at Morgan Stanley with analyst Vincent Meunier upgrading the company two notches to Overweight from Underweight following a "massive" reset in consensus expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Equal Weight
Gilead response to Kymriah pricing 'confusing,' says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said Novartis' (NVS) pricing of its Kymriah therapy at $475,000 gross puts "some slight pressure" on his model for Juno Therapeutics (JUNO), though he doesn't see it as "that far out of line" with his expectations. While he said it makes sense that Juno saw some pressure yesterday after the pricing news and that bluebird bio (BLUE) closed the gap with Juno, he called Gilead's (GILD) strength yesterday "a bit more confounding" given that Gilead is focused on the same indication as Juno. However, initial DLBCL sales in 2018 for both Gilead and Novartis are likely to drive sentiment, so greater clarity won't be seen until then, added Harrison, who keeps an Equal Weight rating on Juno shares.

TODAY'S FREE FLY STORIES

ABCB

Ameris Bancorp

$49.45

0.3 (0.61%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Earnings
Ameris Bancorp reports Q3 adjusted EPS 63c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 15

    Nov

  • 28

    Nov

V

Visa

$107.80

0.26 (0.24%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Hot Stocks
Visa announces security platform Visa ID Intelligence »

Visa announced Visa ID…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Nov

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Earnings
Philip Morris revises FY17 reported EPS view to $4.75-$4.80, consensus $4.84 »

PMI revises its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPX

S&P 500

07:04
10/19/17
10/19
07:04
10/19/17
07:04
Hot Stocks
Trump thinks Republicans have votes for budget approval »

President Trump just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$53.75

-0.23 (-0.43%)

07:03
10/19/17
10/19
07:03
10/19/17
07:03
Earnings
Rogers Communications reports Q3 EPS C$1.01, consensus C$0.80 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PM

Philip Morris

$112.51

-0.14 (-0.12%)

07:02
10/19/17
10/19
07:02
10/19/17
07:02
Earnings
Philip Morris reports Q3 adjusted EPS $1.27, consensus $1.38 »

Reports Q3 revenues,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ERIC

Ericsson

$5.98

0.08 (1.36%)

07:02
10/19/17
10/19
07:02
10/19/17
07:02
Downgrade
Ericsson rating change  »

Ericsson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

07:01
10/19/17
10/19
07:01
10/19/17
07:01
Hot Stocks
Travelers reports Q3 combined ratio of 103.2% »

Including 10.7 points of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

USO

United States Oil Fund

$10.48

-0.01 (-0.10%)

07:01
10/19/17
10/19
07:01
10/19/17
07:01
Technical Analysis
United States Oil Fund: Pivot points, pivot low edged »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$33.35

-0.32 (-0.95%)

07:00
10/19/17
10/19
07:00
10/19/17
07:00
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$26.40

0.3 (1.15%)

06:59
10/19/17
10/19
06:59
10/19/17
06:59
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

06:59
10/19/17
10/19
06:59
10/19/17
06:59
Hot Stocks
Breaking Hot Stocks news story on Travelers »

Travelers reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

UGAZ

VelocityShares 3x Long Natural Gas ETN

$10.23

-0.17 (-1.63%)

06:58
10/19/17
10/19
06:58
10/19/17
06:58
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$130.02

1.37 (1.06%)

06:58
10/19/17
10/19
06:58
10/19/17
06:58
Hot Stocks
Travelers reports Q3 book value per share $86.73 »

Reports Q3 adjusted book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

TRV

Travelers

$130.02

1.37 (1.06%)

06:58
10/19/17
10/19
06:58
10/19/17
06:58
Earnings
Travelers reports Q3 core EPS 91c, may not compare to consensus 43c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 13

    Nov

EWZ

MSCI Brazil Index

$42.70

0.06 (0.14%)

06:57
10/19/17
10/19
06:57
10/19/17
06:57
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$69.54

0.2 (0.29%)

06:57
10/19/17
10/19
06:57
10/19/17
06:57
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.30

0.3 (0.58%)

06:56
10/19/17
10/19
06:56
10/19/17
06:56
Hot Stocks
Breaking Hot Stocks news story on Nike »

Nike drops 2% to $51.15…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

NNI

Nelnet

$51.32

0.06 (0.12%)

06:55
10/19/17
10/19
06:55
10/19/17
06:55
Hot Stocks
Nelnet to acquire Great Lakes Educational for $150M »

Nelnet announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$37.27

0.02 (0.05%)

06:55
10/19/17
10/19
06:55
10/19/17
06:55
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.06

-0.035 (-0.15%)

06:55
10/19/17
10/19
06:55
10/19/17
06:55
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:55
10/19/17
10/19
06:55
10/19/17
06:55
General news
Oil Action: Front-month WTI futures are down 1.2% »

Oil Action: Front-month…

PLX

Protalix

$0.83

0.176 (26.91%)

06:55
10/19/17
10/19
06:55
10/19/17
06:55
Conference/Events
Protalix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.60

0.09 (0.10%)

06:54
10/19/17
10/19
06:54
10/19/17
06:54
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$93.43

-0.84 (-0.89%)

, ADI

Analog Devices

$89.00

0.06 (0.07%)

06:54
10/19/17
10/19
06:54
10/19/17
06:54
Recommendations
Texas Instruments, Analog Devices, Microchip, Maxim Integrated, ON Semiconductor analyst commentary  »

Jefferies sees…

TXN

Texas Instruments

$93.43

-0.84 (-0.89%)

ADI

Analog Devices

$89.00

0.06 (0.07%)

MCHP

Microchip

$92.12

0.42 (0.46%)

MXIM

Maxim Integrated

$49.85

-0.01 (-0.02%)

ON

ON Semiconductor

$19.71

0.11 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.